Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy

NCT01355497 is registered in ClinicalTrials.gov with GTx as lead sponsor.

NCT NCT01355497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01355497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Lead sponsor
GTx
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2011
Completion date
June 30, 2014
Enrollment
330 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

muscle wasting, non-small cell lung cancer